Eli Lilly stops Phase II trial of BTK inhibitor in RA

Eli Lilly and Co. (NYSE:LLY) discontinued the Phase II RAjuvenate trial of HM71224 (LY3337641) to treat rheumatoid

Read the full 176 word article

User Sign In